A century of traditional vaccinology lost the fight against meningococcus serogroup B (MenB). However, thanks to an innovative genome-based approach, the first broadly effective MenB vaccine, Bexsero® (GSK Vaccines), was developed and has been licensed for use in various age groups by the European Commission and other regulatory authorities. Genes encoding for the main meningococcus B antigens ...

Haemophilus influenza (Hib) conjugates vaccine (HibCV) using a pentavalent formulation was introduced to Iranian routine immunization program from November 2014. Iran is preparing to include pneumococcal conjugate vaccines (PCVs) as well. Assessing the impact of HibCV to provide evidences regarding sustained administration of this vaccine is necessary. There are different methods and study desi...

OBJECTIVE To briefly review strategies aimed at the development of rotavirus and HPV vaccines, with emphasis on the current status of studies assessing the safety, reactogenicity, immunogenicity and efficacy of recently developed vaccines. SOURCES OF DATA This review focuses on articles published from 1996 to 2006, mainly those from the last five years, with special emphasis on data obtained ...

The World Health Organisation (WHO) has recently revised how adverse events after immunization (AEFI) are classified. Only reactions that have previously been acknowledged in epidemiological studies to be caused by the vaccine, are classified as a vaccine-product–related-reaction. Deaths observed during post-marketing surveillance are not considered as “consistent with causal association with v...

OBJECTIVES To compare the safety and immunogenicity of a booster dose of a fully liquid diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b (DTPw-HepB-Hib) vaccine to the separate administration of commercially available DTPw and Hib vaccines in healthy toddlers. METHODS An open-label, randomized, parallel-group, Phase III study conducted at six centers in San Sa...